A Phase 1 interventional study of MB02 and US licenced Avastin® in Healthy Volunteers, sponsored by mAbxience Research S.L.. Completed at 2 sites in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-23.
Sponsored by mAbxience Research S.L. (part of Fresenius Kabi) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare the Pharmacokinetics (PK), safety and immunogenicity profile of MB02 with US and EU Avastin® in healthy male subjects.
During the course of the study, the similarity in pharmacokinetics will be assessed by sampling the levels of drug in the blood, and by comparing these levels among the different administration arms. Safety, tolerability, and immunologic response to the administered drugs will also be evaluated throughout.
The primary PK parameters are Cmax and AUC(0-∞). The PK parameters for bevacizumab will be calculated using standard noncompartmental methods. An analysis of covariance model will be used to analyse the log-transformed primary PK parameters (AUC[0-∞].and Cmax) and AUC(0-t). The model will include a fixed effect for treatment and body weight as a covariate.
All other PK parameters will not be subject to inferential statistical analysis. Estimates of geometric mean ratios together with the corresponding 90% confidence intervals will be derived for the comparisons of the PK parameters as follows:
PK similarity will be achieved if the 90% confidence intervals (CIs) for the biosimilar-to-reference ratios of PK endpoints (AUC[0-∞] and Cmax) fall within the predefined 0.80-1.25 acceptance similarity criteria for all 3 pairwise comparisons; MB02 versus EU-approved Avastin®; MB02 versus US-licenced Avastin®; and EU-approved Avastin® versus US-licenced Avastin®.
All AEs will be listed and summarised using descriptive methodology. All observed or patient-reported AEs will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. The incidence of AEs for each treatment will be presented by severity and by association with the study drugs as determined by the Investigator (or designee). All safety data will be listed and summarised as appropriate
Immunogenicity data (overall anti-drug antibody [ADA] incidence and titers, and neutralising ADA results) will be listed. A summary of the number and percent of subjects testing positive for ADA or neutralising antibodies before the dose of MB02, EU Avastin®, or US Avastin® (Day 1) and at scheduled postdose assessments will be presented by treatment arm.
mAbxience Research S.L. is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
First submitted before mAbxience Research S.L. became part of Fresenius Kabi.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Relevant clinical laboratory evaluations of haematology, coagulation, urinalysis and clinical chemistry within normal range at Screening and Check in as follows. A single repeat test will be allowed at each timepoint.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
Drug: MB02
Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
Drug: US licenced Avastin®
Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
Drug: EU approved Avastin®
Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
Also known as: MB02 (Bevacizumab Biosimilar)
Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
Also known as: Bevacizumab (United States)
Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
Also known as: Bevacizumab (European Union)
Cmax: Maximum Observed Serum Concentration
To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of Cmax) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric LS means ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity
To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of AUC\[0-∞\]) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric least square means (GLSM) ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Tmax: Time of Maximum Observed Serum Concentration
To evaluate the tmax of MB02, US Avastin® and EU Avastin® .
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
AUC(0-t) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration;
To evaluate the AUC\[0-t\] of MB02, US Avastin® and EU Avastin®.
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
CL: Total Body Drug Clearance After IV Administration
To evaluate the CL of MB02, US Avastin® and EU Avastin®
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
t1/2: Apparent Serum Terminal Elimination Half-life
To evaluate the t1/2 of MB02, US Avastin® and EU Avastin®
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Immunogenicity
Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here.
Time frame: Day -1, Day 14, 28, 56, and 78
Safety (Incidence of Treatment-related Adverse Events Using CTCAE v4.03)
Compare the incidence of TEAEs reported in each treatment arm.
Time frame: Day 1 - Day 100
AUC(0-∞) Adjusted: Protein-adjusted Area Under the Serum Concentration-time Curve From Time Zero to Infinity
Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as AUC is a dose-dependent PK parameter), protein-adjusted AUC(0-∞) was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax.
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
AUC(0-t) Adjusted: Protein Adjusted Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration
Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as AUC is a dose-dependent PK parameters), protein-adjusted AUC(0-t) was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax.
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Cmax Adjusted: Protein Adjusted Maximum Observed Serum Concentration
Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as Cmax is a dose-dependent PK parameters), protein-adjusted Cmax was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax.
Time frame: Predose, 1.5 h after end of infusion, 2, 3, 4, 5, 6, 8, 12, 24 h post-dose on Day 1-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
| Milestone | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® |
|---|---|---|---|
| Started | 38 | 38 | 38 |
| Completed | 38 | 37 | 38 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of Cmax) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric LS means ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.
| (ng/mL)/(mg/mL) | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® |
|---|---|---|---|
| Cmax: Maximum Observed Serum Concentration | 83000 ± 22.4 | 65200 ± 21.9 | 74400 ± 25.3 |
To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of AUC\[0-∞\]) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric least square means (GLSM) ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.
| ng*h/mL | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® |
|---|---|---|---|
| AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity | 28200000 ± 16.3 | 22900000 ± 17.8 | 24500000 ± 15.2 |
To evaluate the tmax of MB02, US Avastin® and EU Avastin® .
| h | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® |
|---|---|---|---|
| Tmax: Time of Maximum Observed Serum Concentration | 2.51 (1.62 to 71.98) | 4.00 (1.62 to 11.98) | 3.00 (1.57 to 12.00) |
To evaluate the AUC\[0-t\] of MB02, US Avastin® and EU Avastin®.
| ng*h/mL | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® |
|---|---|---|---|
| AUC(0-t) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration; | 27400000 ± 15.5 | 22300000 ± 16.9 | 23700000 ± 14.2 |
To evaluate the CL of MB02, US Avastin® and EU Avastin®
| l/h | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® |
|---|---|---|---|
| CL: Total Body Drug Clearance After IV Administration | 0.00814 ± 16.5 | 0.0101 ± 17.9 | 0.00947 ± 15.4 |
To evaluate the t1/2 of MB02, US Avastin® and EU Avastin®
| h | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® |
|---|---|---|---|
| t1/2: Apparent Serum Terminal Elimination Half-life | 451 ± 14.4 | 437 ± 15.5 | 449 ± 19.3 |
Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here.
| Participants | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® |
|---|---|---|---|
| ADA positive | 2 | 2 | 1 |
| nAb positive | 1 | 0 | 0 |
| NO seroconversion | 35 | 36 | 37 |
Compare the incidence of TEAEs reported in each treatment arm.
| participants | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® |
|---|---|---|---|
| Subjects with TEAEs | 24 | 28 | 25 |
| Subjects with SAEs | 0 | 1 | 0 |
| Subjects discontinued due to TEAEs | 0 | 0 | 0 |
| Related TEAEs | 6 | 3 | 8 |
| TEAEs of mild severity | 24 | 25 | 24 |
| TEAEs of moderate severity | 4 | 10 | 5 |
| TEAEs of severe severity | 0 | 1 | 0 |
Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as AUC is a dose-dependent PK parameter), protein-adjusted AUC(0-∞) was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax.
| ng*h/mL | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® |
|---|---|---|---|
| AUC(0-∞) Adjusted: Protein-adjusted Area Under the Serum Concentration-time Curve From Time Zero to Infinity | 1040000 ± 16.3 | 981000 ± 18.1 | 1020000 ± 14.5 |
Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as AUC is a dose-dependent PK parameters), protein-adjusted AUC(0-t) was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax.
| ng*h/mL | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® |
|---|---|---|---|
| AUC(0-t) Adjusted: Protein Adjusted Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration | 1010000 ± 15.5 | 955000 ± 17.2 | 991000 ± 13.6 |
Due to variability in the actual protein content between the study drugs and study drug batches which had the potential to influence the study results (as Cmax is a dose-dependent PK parameters), protein-adjusted Cmax was also derived for each individual by dividing each parameter by the actual protein content of the product batch that the individual subjects received. The 3 mg/kg IV dose of MB02 and US Avastin®, MB02 and EU Avastin®, and EU and US Avastin® were all considered bioequivalent in terms of the protein-adjusted AUCs and Cmax as the 90% CI for the geometric LS means ratios were fully contained within the predefined bioequivalence limits of 0.80 to 1.25 for all 3 comparisons. In general, as assessed from the geometric CV%, between-subject variability remained similar following protein adjustment compared to the unadjusted AUCs and Cmax.
| (ng/mL)/(mg/mL) | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® |
|---|---|---|---|
| Cmax Adjusted: Protein Adjusted Maximum Observed Serum Concentration | 3050 ± 22.4 | 2790 ± 22.1 | 3110 ± 25.2 |
Collected over Study duration (Day 1 - Day 100). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | 0/38 (0%) | 0/38 (0%) | 24/38 (63.2%) |
| US Licenced Avastin® | 0/38 (0%) | 1/38 (2.6%) | 28/38 (73.7%) |
| EU Approved Avastin® | 0/38 (0%) | 0/38 (0%) | 25/38 (65.8%) |
| Event | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® |
|---|---|---|---|
| PurpuraSkin and subcutaneous tissue disorders | 0/38 | 1/38 | 0/38 |
| Event | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 4/38 | 11/38 | 6/38 |
| HeadacheNervous system disorders | 6/38 | 8/38 | 8/38 |
| Back painMusculoskeletal and connective tissue disorders | 1/38 | 7/38 | 4/38 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/38 | 4/38 | 5/38 |
| NasophyringitisInfections and infestations | 2/38 | 4/38 | 5/38 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/38 | 2/38 | 1/38 |
| NauseaGastrointestinal disorders | 4/38 | 0/38 | 1/38 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/38 | 4/38 | 3/38 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/38 | 0/38 | 3/38 |
| DiarrhoeaGastrointestinal disorders | 3/38 | 1/38 | 0/38 |
| Age, Categorical(Participants) | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 38 | 38 | 38 | 114 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® | Total |
|---|---|---|---|---|
| Mean | 36 ± 10.8 | 35 ± 9.1 | 38 ± 9.9 | 37 ± 9.9 |
| Sex: Female, Male(Participants) | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 38 | 38 | 38 | 114 |
| Race (NIH/OMB)(Participants) | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 5 | 2 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 4 | 9 |
| White | 35 | 30 | 30 | 95 |
| More than one race | 0 | 1 | 2 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Weight(kg) | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® | Total |
|---|---|---|---|---|
| Mean | 76.9 ± 9.38 | 77.9 ± 8.11 | 77.8 ± 8.29 | 77.6 ± 8.55 |
| BMI(kg/m^2) | MB02 (Bevacizumab Biosimilar) | US Licenced Avastin® | EU Approved Avastin® | Total |
|---|---|---|---|---|
| Mean | 24.3 ± 2.66 | 24.3 ± 2.61 | 25.0 ± 2.07 | 24.5 ± 2.46 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2017 to primary completion in May 2019, 17 months.
Results were first posted in Jun 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MB02